Two-drug HIV therapy just as effective as three-drug therapy

aidsmap/nam, 25 October 2016

SImplification of an antiretroviral treatment to a boosted protease inhibitor and the nucleoside analogue lamivudine (a dual regimen) is highly effective in people switching from a stable three-drug regimen, researchers reported on Monday at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow).

Read more here 

Patient choice in opt-in, active choice, and opt-out HIV screening: an RCT

BMJ 2016; 352 doi: http://dx.doi.org/10.1136/bmj.h6895 (Published 19 January 2016)

What is already known on this topic

  • Patients’ preferences are a hallmark of patient centered care, but little is known about how wording of offers of testing can influence perceived preferences

  • Opt-in and opt-out HIV testing have not been compared in a randomized controlled setting

  • US guidelines endorse opt-out HIV testing, and Europe has seen a trend toward this testing scheme

What this study adds

  • Opt-in and opt-out defaults had statistically and clinically significant effects on the likelihood of patients accepting tests

  • Patients reporting risk factors were more likely to accept testing in each testing regimen than were patients reporting no risk factors

  • Active choice is a distinct test regimen, with test acceptance patterns that may best approximate patients’ true preferences

Ipergay PrEP study results published

NAM , 02 December 2015

The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional comments and are notably cautious about not over-interpreting a study that only had 400 participants – very small for a prevention study – and an average of nine months’ follow-up.

It is the first, and so far only. randomised study to show that PrEP can be just as effective if it is given as an intermittent regimen that users only take when anticipating sex, rather than daily.

Read more here